CD19 and COVID-19: Furthermore, COVID-19 survivors demonstrated decreased circulating CD19+CD27− B cells compared to patients with a poor outcome in the acute stage of the disease, while the CD19+CD27+ B cell numbers in this group were lower compared to controls or patients with a poor outcome (Figure 4C,D).